DDInter666 DDInter832
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors.
A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism.
Eribulin {u} (Compound) treats {v} (Disease) breast cancer
Eribulin {u} (Compound) binds {v} (Gene) TUBB
Eribulin {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Eribulin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Verapamil
Eribulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paliperidone
Eribulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Poliovirus type 1 antigen (formaldehyde inactivated)
Eribulin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Eribulin {u} may lead to a major life threatening interaction when taken with {v} Escitalopram
Eribulin (Compound) treats breast cancer (Disease)
Eribulin (Compound) binds TUBB (Gene)
Eribulin (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Eribulin may cause a minor interaction that can limit clinical effects when taken with Verapamil
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Eribulin may lead to a major life threatening interaction when taken with Teriflunomide
Eribulin may lead to a major life threatening interaction when taken with Escitalopram